Survivorship & Long-Term Monitoring
At a Glance
Achalasia requires lifelong monitoring even after successful treatment. Patients should regularly track their Eckardt score for returning symptoms and often need daily acid reflux medication to prevent esophageal damage. The absolute risk of esophageal cancer remains very low.
Receiving treatment for achalasia is a major milestone, but it is not the end of the journey. Because achalasia is a chronic, lifelong condition, your relationship with your medical team will transition from “crisis management” to long-term “survivorship.” This phase focuses on monitoring for the return of symptoms, managing treatment side effects like reflux, and staying vigilant against long-term complications.
Long-Term Monitoring: The Eckardt Score
Even after a successful procedure, you should continue to monitor your symptoms using the Eckardt score [1]. Many specialists recommend assessing your score every 3 to 6 months in the first year after treatment, and then annually thereafter. A score that rises above 3 is a signal that your esophagus may be struggling to empty, and you should contact your gastroenterologist for a follow-up evaluation [2].
The Risk of Esophageal Cancer: Context is Key
Patients with achalasia have an elevated relative risk of developing esophageal squamous cell carcinoma (ESCC) compared to the general population [3][4]. However, the absolute risk remains very low—often estimated at less than 1% to 3% over a patient’s lifetime.
- Why it Happens: Over decades, food and liquid that “sit” in the esophagus cause chronic inflammation and irritation, which can eventually lead to cancerous changes [5].
- Surveillance Guidelines: Because the absolute risk is so low, routine cancer screening is heavily debated. Current primary guidelines (such as the American College of Gastroenterology 2020 guidelines) actually recommend against routine endoscopic surveillance for all achalasia patients. However, some societies suggest it can be considered on a case-by-case basis starting 10 to 15 years after symptom onset [6]. Discuss a personalized surveillance plan with your doctor.
Managing Chronic Reflux (GERD)
Acid reflux is often the “trade-off” for effective achalasia treatment, particularly after a POEM procedure [7]. If left untreated, chronic reflux can lead to Barrett’s esophagus, a condition where the lining of the esophagus changes and becomes more prone to a different type of cancer called adenocarcinoma [3].
- Maintenance Therapy: Most patients who have had POEM—and many who have had a Heller Myotomy—will require long-term, daily use of Proton Pump Inhibitors (PPIs) to protect the esophagus [8].
- “Silent” Reflux: Be aware of “silent” symptoms such as a morning sore throat, a chronic dry cough, or a metallic taste in your mouth, which can indicate reflux even if you don’t feel typical heartburn.
Advanced Complications: Megaesophagus
In some cases, even after a successful myotomy, the esophagus may continue to stretch and dilate over many years, eventually becoming what is known as a megaesophagus or sigmoid esophagus (where it takes on an “S” shape) [9][10].
- Treatment Options: While a second (“salvage”) POEM can sometimes help, the failure rate is higher in these advanced stages [11].
- Definitive Surgery: If the esophagus becomes so distorted that it can no longer clear food, a major surgery called an esophagectomy (removing the esophagus) may be discussed. Please note that this is an extremely rare, last-resort scenario designed to restore the ability to eat and prevent life-threatening infections when all other treatments have failed [12].
The Psychological Burden and Eating Anxiety
Living with a rare disease that affects the most basic human act—eating—takes a significant psychological toll. Many survivors experience “eating anxiety,” social isolation, or a constant fear of symptom recurrence [13].
- Navigating Social Eating: If eating in public causes anxiety, try practical strategies: always order a glass of warm water (which can help relax spasms), take small bites, chew thoroughly, and don’t hesitate to excuse yourself from the table if you feel food backing up. Many patients find it helpful to explain their condition simply to close friends to remove the pressure.
- Support: Connecting with other achalasia patients through support groups can be an essential part of your long-term wellness plan, helping to normalize your experience and reduce the feeling of isolation [14].
Common questions in this guide
How often should I check my Eckardt score after achalasia treatment?
Do I need regular cancer screenings if I have achalasia?
Why do I need to take acid reflux medication after a POEM procedure?
What is a megaesophagus?
How can I manage anxiety around eating in public with achalasia?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many years has it been since my symptoms first started, and based on that, when should my regular endoscopic cancer surveillance begin?
- 2.Given my specific treatment (POEM vs. Heller Myotomy), what is my plan for managing and monitoring for acid reflux?
- 3.Should I be taking a daily PPI medication even if I don't feel classic 'heartburn' symptoms?
- 4.During my follow-up endoscopies, are you looking specifically for signs of Barrett's esophagus or squamous cell changes?
- 5.If my symptoms were to return, what 'salvage' options (like a second POEM or a TIF) would be available to me before considering major surgery?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Fair reliability of eckardt scores in achalasia and non-achalasia patients: Psychometric properties of the eckardt spanish version in a multicentric study.
Cisternas D, Monrroy H, Riquelme A, et al.
Neurogastroenterology and motility 2020; (32(6)):e13827 doi:10.1111/nmo.13827.
PMID: 32100424 - 2
Repeat peroral endoscopic myotomy: a salvage option for persistent/recurrent symptoms.
Li QL, Yao LQ, Xu XY, et al.
Endoscopy 2016; (48(2)):134-40 doi:10.1055/s-0034-1393095.
PMID: 26349067 - 3
Achalasia and Risk of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in a Multinational Study.
Leijonmarck W, Santoni G, Holmberg D, et al.
Gastroenterology 2026; doi:10.1053/j.gastro.2026.03.024.
PMID: 42019768 - 4
The Relationship Between Achalasia and Esophageal Cancer: The Experience of a Tertiary Center.
Öztürk Ö, Kaplan M, Tenlik İ, et al.
The Eurasian journal of medicine 2022; (54(1)):45-49 doi:10.5152/eurasianjmed.2022.21127.
PMID: 35307628 - 5
Mast cell infiltration associated with loss of interstitial cells of Cajal and neuronal degeneration in achalasia.
Liu ZQ, Chen WF, Wang Y, et al.
Neurogastroenterology and motility 2019; (31(5)):e13565 doi:10.1111/nmo.13565.
PMID: 30868687 - 6
A Case of Esophageal Squamous Cell Carcinoma Detected After Peroral Endoscopic Myotomy in a Patient With Achalasia.
Kamio T, Hirata S, Hamada K, et al.
Cureus 2024; (16(10)):e71604 doi:10.7759/cureus.71604.
PMID: 39553052 - 7
Per-oral endoscopic myotomy versus laparoscopic Heller's myotomy plus Dor fundoplication in patients with idiopathic achalasia: 5-year follow-up of a multicentre, randomised, open-label, non-inferiority trial.
Hugova K, Mares J, Hakanson B, et al.
The lancet. Gastroenterology & hepatology 2025; (10(5)):431-441 doi:10.1016/S2468-1253(25)00012-3.
PMID: 40112837 - 8
Gastroesophageal reflux disease after peroral endoscopic myotomy is unpredictable, but responsive to proton pump inhibitor therapy: a large, single-center study.
Nabi Z, Ramchandani M, Kotla R, et al.
Endoscopy 2020; (52(8)):643-651 doi:10.1055/a-1133-4354.
PMID: 32208499 - 9
Laparoscopic Heller Myotomy for Achalasia Technical Aspects.
Schlottmann F, Allaix ME, Patti MG
The American surgeon 2018; (84(4)):477-480.
PMID: 29712592 - 10
A Thousand and One Laparoscopic Heller Myotomies for Esophageal Achalasia: a 25-Year Experience at a Single Tertiary Center.
Costantini M, Salvador R, Capovilla G, et al.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2019; (23(1)):23-35 doi:10.1007/s11605-018-3956-x.
PMID: 30238248 - 11
Factors associated with peroral endoscopic myotomy for achalasia outcomes: systematic review and meta-analysis.
Shou Y, Wang X, Liu D
Surgical endoscopy 2024; (38(7)):3503-3519 doi:10.1007/s00464-024-10862-3.
PMID: 38782829 - 12
State-of-the-Art Surgery in Achalasia.
Plum PS, Niebisch S, Gockel I
Visceral medicine 2024; (40(6)):293-298 doi:10.1159/000541928.
PMID: 39664092 - 13
Efficacy of peroral endoscopic myotomy for improving sleep problems in patients with achalasia.
Ohmiya T, Shiwaku H, Okada H, et al.
DEN open 2025; (5(1)):e70064 doi:10.1002/deo2.70064.
PMID: 39840006 - 14
Prior treatment does not influence the performance or early outcome of per-oral endoscopic myotomy for achalasia.
Jones EL, Meara MP, Pittman MR, et al.
Surgical endoscopy 2016; (30(4)):1282-6 doi:10.1007/s00464-015-4339-y.
PMID: 26123336
This page explains long-term monitoring and survivorship for achalasia for educational purposes only. Always consult your gastroenterologist for personalized surveillance and treatment plans.
Get notified when new evidence is published on Idiopathic achalasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.